PT-141 (Bremelanotide) Dosage Guide: Protocol, Reconstitution & Use for Men and Women

Medically reviewed by the BHRC Clinical Team — Beverly Hills Rejuvenation Center · Published / Reviewed July 24, 2026

Written by Sam Brooks, BHRC Peptide Education Team

Medical & educational disclaimer: This guide is educational and is not medical advice, a prescription, or self-administration instructions. PT-141 (bremelanotide) is a prescription melanocortin agonist. Every dose, protocol, and candidacy decision must be made and supervised by a licensed physician who has evaluated your health history, blood pressure, and cardiovascular risk. The dosing figures below describe how the FDA-approved product (Vyleesi) is labeled and how physicians describe compounded protocols in the clinical literature — they are provider-directed reference points, not a plan for anyone to dose themselves.

Quick PT-141 Dosing Summary

PT-141 (bremelanotide) is a melanocortin-receptor agonist used, under physician supervision, for low sexual desire and arousal. The FDA-approved form (Vyleesi) is dosed at 1.75 mg subcutaneously, at least 45 minutes before anticipated sexual activity, no more than once in 24 hours and no more than 8 times per month. Physician-directed compounded protocols often begin with a 0.5 mg test dose, settle into a 1.0–1.75 mg maintenance dose taken 30–60 minutes before activity, and are capped at roughly 2 mg per dose and 2–3 uses per week.

Schedule a Peptide Therapy Consultation with a BHRC physician to see whether PT-141 or the FDA-approved alternative is appropriate for you.

What Is PT-141 (Bremelanotide)?

PT-141, generic name bremelanotide, is a synthetic cyclic seven–amino-acid peptide derived from alpha-melanocyte-stimulating hormone (α-MSH). It is a melanocortin-receptor agonist, meaning it activates the family of melanocortin receptors (MC1R through MC5R) rather than acting on blood vessels the way erectile-dysfunction pills do. Its relevant activity for sexual function is at the MC4R receptor in the central nervous system, a pathway involved in sexual motivation and arousal.

How PT-141 Differs From Viagra and Cialis

This is the single most important distinction for patients to understand. Sildenafil (Viagra) and tadalafil (Cialis) are PDE5 inhibitors — they work peripherally on blood flow to enable an erection once desire and arousal are already present. PT-141 works centrally, in the brain, on the melanocortin pathway that governs desire and arousal in the first place. It does not primarily increase blood flow. That is why it is studied for low desire and for patients who do not respond to PDE5 inhibitors, and why it is used in women as well as men.

From Nasal Spray to Injection: A Short History

Bremelanotide was first developed by Palatin Technologies as an intranasal spray in the mid-2000s. Phase 2 nasal trials showed dose-dependent increases in blood pressure, and the intranasal program was abandoned around 2008 in favor of a lower-dose subcutaneous route. That subcutaneous form was studied in the Phase 3 RECONNECT trials and approved by the FDA in 2019 as Vyleesi. There is no FDA-approved bremelanotide nasal spray — a point we return to in the dosing-form section below.

The Melanocortin System in Plain English

The melanocortin system is an ancient signaling network built around five receptor subtypes (MC1R–MC5R) and their natural ligands, the melanocortins, which are cleaved from a precursor protein called proopiomelanocortin (POMC). Each receptor governs different biology: MC1R sits on the melanocytes of the skin and controls pigment (which is why melanocortin drugs can darken skin), MC2R handles adrenal steroid production, MC3R and MC4R sit largely in the brain and regulate appetite, energy balance, and sexual behavior, and MC5R is involved in exocrine gland function. Bremelanotide is a non-selective agonist — it touches several of these receptors, with an order of potency reported as MC1R > MC4R > MC3R > MC5R > MC2R. The desired sexual-function effect is attributed to MC4R activation in the central nervous system; the flushing and pigmentation effects come mostly from MC1R. Understanding this is what makes the side-effect profile intuitive rather than surprising.

Pharmacokinetics: Onset, Peak, and Clearance

After a subcutaneous injection, bremelanotide is absorbed and reaches peak plasma concentration in roughly one hour. Its elimination half-life is about 2.7 hours, with a published range of approximately 1.9–4.0 hours. It is cleared through multiple pathways and is not heavily dependent on a single enzyme system, though dosing considerations change in significant hepatic or renal impairment and should be handled by the prescriber. The relatively short half-life is the pharmacologic reason PT-141 is an episodic, as-needed therapy rather than a steady-state daily peptide — a single dose covers a window of several hours and then clears.

PT-141 vs Vyleesi: Same Molecule, Different Product

PT-141 and Vyleesi are the same active molecule (bremelanotide). “Vyleesi” is the branded, FDA-approved, single-dose autoinjector manufactured to cGMP standards with standardized potency and purity. “PT-141” is the name used for the compounded or research forms of the same peptide, which are prepared in multi-use vials, require reconstitution, and vary in quality depending on the source. They share pharmacology but not regulatory footing or manufacturing assurance — a distinction we cover fully in the comparison table and the legal section.

PT-141 Dosing Protocols Based on Clinical Research

There are two distinct dosing references for bremelanotide: the FDA label for Vyleesi (a single fixed dose, approved for one specific indication in women) and the physician-directed compounded protocols that clinicians describe for off-label use in men and women. We present both, clearly separated, and we do not blur them.

Standard Ranges

• Test / starting dose: 0.5 mg subcutaneously (some clinicians start at 0.25–1.0 mg). The purpose is to gauge nausea and blood-pressure response before any regular use.
• Maintenance dose: 1.0–1.75 mg subcutaneously, as-needed before activity, once the test dose is tolerated.
• Effective range reported: roughly 1.0–2.0 mg per dose.
• Ceiling: approximately 2 mg per dose. Going higher tends to increase nausea and blood-pressure effects without adding meaningful benefit.

Research-Based Protocols

The FDA-approved regimen — the only regimen supported by a completed Phase 3 program — is 1.75 mg subcutaneously, at least 45 minutes before anticipated sexual activity, with no more than one dose in any 24-hour period and no more than 8 doses per month. Everything below the 1.75 mg figure (test doses, gradual titration) reflects how clinicians manage tolerability in practice rather than a separately approved schedule.

It is worth being explicit about why the test-dose-then-titrate approach exists at all when the approved product is a single fixed dose. The FDA program studied one dose (1.75 mg) and one population, and that dose produced a high rate of first-injection nausea. Compounded protocols exist partly to smooth that experience — a patient takes a smaller amount first, confirms they tolerate it, and then decides with their physician whether to move toward the full dose. This is a tolerability strategy, not evidence that a lower dose is equally effective. In practice, many patients who tolerate the peptide land at a working dose in the 1.0–1.75 mg range and stay there.

A Note on “More Is Not Better”

With PT-141, the dose-response relationship for side effects is steeper than the dose-response relationship for benefit above about 1.75 mg. Pushing toward or past 2 mg predictably increases nausea, flushing, and the magnitude of the transient blood-pressure rise, while offering little additional efficacy. This is a peptide where the discipline is to find the lowest effective dose and hold there, not to escalate.

Clinical Trial Data (RECONNECT)

Bremelanotide 1.75 mg subcutaneous was evaluated in the two identical Phase 3 RECONNECT studies (NCT02333071 and its companion trial) in premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Participants were randomized 1:1 to bremelanotide or placebo for 24 weeks, dosing as needed. Co-primary endpoints were change in the Female Sexual Function Index–desire domain (FSFI-D) and the Female Sexual Distress Scale–Desire/Arousal/Orgasm item 13 (FSDS-DAO Q13). Both endpoints improved statistically significantly versus placebo. The reported effect sizes were modest — Cohen’s d of about 0.39 for desire and 0.27 for distress in the combined analysis — a point worth stating honestly: this is a meaningful but not dramatic effect, and it was studied in a specific population of premenopausal women, not in men.

PT-141 Dosage for Men

Use of PT-141 in men is entirely off-label — there is no FDA-approved bremelanotide product for men. Vyleesi is approved only for premenopausal women. Any men’s protocol is a physician’s off-label, compounded decision.

Men’s Starting and Maintenance Doses

Clinicians who use PT-141 off-label for men with low libido or PDE5-non-responsive erectile dysfunction typically describe starting at a 0.5–1.0 mg test dose and titrating to a 1.0–1.75 mg working dose, injected subcutaneously 45 minutes or more before activity. The reported “sweet spot” for many men is around 1.5–1.75 mg — enough for effect while limiting nausea. The ceiling remains roughly 2 mg, and frequency is kept to no more than a couple of times per week.

Men’s Timing and Expectations

Because PT-141 works on desire and central arousal rather than on blood flow, some men use it as an adjunct to — not necessarily a replacement for — a PDE5 inhibitor, only under a physician’s direction. Onset is typically 30–60 minutes, with effects lasting several hours. It is not a daily therapy and not a substitute for evaluating underlying causes of low libido such as low testosterone, sleep, mood, or medication side effects.

The Evidence Gap for Men

Patients deserve honesty here: the large Phase 3 RECONNECT program that supports Vyleesi enrolled premenopausal women, not men. Earlier bremelanotide research did include work on male sexual dysfunction, including the abandoned intranasal program that showed effects on erectile response, but there is no completed, FDA-reviewed Phase 3 dataset establishing an approved men’s dose or a formal efficacy claim in men. Off-label men’s use therefore rests on pharmacologic rationale (the MC4R pathway is not sex-specific), earlier-phase data, and clinical experience — a reasonable basis for a physician-directed trial in an appropriate patient, but not the same evidentiary footing as the women’s indication. Any clinic that presents PT-141 for men as “FDA-approved” is misrepresenting it.

Men’s Screening Before a Trial of PT-141

Before an off-label trial in a man, a thorough evaluation should rule out or address the common, treatable drivers of low libido and erectile complaints: low testosterone (a morning total and free testosterone, and often LH/FSH and prolactin), thyroid dysfunction, poorly controlled diabetes, depression or anxiety, relationship factors, and medications such as SSRIs or certain blood-pressure drugs that suppress libido. PT-141 is not a shortcut around that workup.

PT-141 Dosage for Women

Women are the only population with an FDA-approved bremelanotide product. That matters for both dosing and safety.

The FDA-Approved Regimen (Vyleesi)

For premenopausal women with acquired, generalized HSDD, the labeled regimen is 1.75 mg subcutaneously in the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity. Do not use more than one dose within 24 hours or more than 8 doses per month. The product is a single-use, pre-filled autoinjector containing 1.75 mg in 0.3 mL — there is no built-in lower dose. If nausea is a problem, physicians may pretreat with an anti-nausea medication rather than reduce the fixed dose.

Compounded PT-141 in Women

Some women use compounded PT-141 (often at 0.5–1.75 mg) under a physician’s direction, for reasons such as tolerability titration. As with men, compounded use falls outside the FDA approval, and the approved Vyleesi product should be the default reference where the indication fits.

Who the Approval Does Not Cover

Vyleesi is not approved for postmenopausal women and not approved for HSDD caused by another medical or psychological condition, relationship problems, or a medication. A physician has to establish that the “acquired, generalized” HSDD picture actually fits before this is an appropriate therapy.

What “Acquired, Generalized HSDD” Actually Means

These qualifiers are not marketing language — they define who the therapy was studied in. “Acquired” means the low desire developed after a period of normal function, rather than being lifelong. “Generalized” means it occurs across situations and partners, not only in a specific relationship or circumstance. And the diagnosis requires that the low desire causes marked personal distress or interpersonal difficulty and is not better explained by a co-existing medical or psychiatric condition, relationship conflict, or the effects of a medication or substance. When those boxes are not checked, PT-141 is not the right tool, and forcing it is both poor medicine and outside the label.

Managing First-Dose Nausea in Women

Because roughly 40% of women in the trials experienced nausea — most intensely with the first injection — physicians often plan for it: setting expectations, timing the first dose when the patient can rest, and in some cases pre-medicating with an anti-nausea agent. For most patients the nausea attenuates with subsequent doses. The fixed autoinjector cannot be dialed down, so tolerability is managed around the dose rather than by shrinking it.

PT-141 vs Vyleesi: Compounded vs FDA-Approved

Because PT-141 and Vyleesi are the same molecule with very different regulatory footing, the comparison below is the clearest way to frame the choice — and the compliance reality.

The practical takeaway: when a patient fits the approved indication, the FDA-approved product is the higher-assurance choice on purity, potency, and dosing. BHRC positions PT-141 strictly as a physician-supervised therapy — not something to source or self-dose from an online vendor.

How to Reconstitute PT-141

Reconstitution applies to compounded PT-141 vials only (Vyleesi arrives pre-filled and needs no mixing). The steps below describe how a clinician or trained patient prepares a lyophilized (freeze-dried) 10 mg vial. This is presented as education about the process, performed under provider direction — not a prompt to self-treat.

Step-by-Step Reconstitution

1. Gather supplies: the lyophilized PT-141 vial, bacteriostatic water for injection (BAC water) as directed by your provider/pharmacy, alcohol swabs, a reconstitution syringe, and U-100 insulin syringes for dosing.
2. Wash hands and let all vials reach room temperature. Swab the rubber stopper of both the peptide vial and the BAC water vial.
3. Draw the prescribed volume of BAC water (for a 10 mg vial, commonly 1–2 mL).
4. Insert the needle and let the water run slowly down the inside wall of the vial — do not squirt it directly onto the peptide powder, which can damage the peptide.
5. Do not shake. Gently swirl or let it sit until fully dissolved and clear.
6. Label with the concentration and reconstitution date, and refrigerate (typically 2–8 °C). Discard per your pharmacy’s beyond-use date.

Dosing Calculation Examples (mg → insulin units)

On a standard U-100 insulin syringe, 1 mL = 100 units. The reconstitution volume you choose sets the concentration, which sets how many units equal your target dose. The table shows three common ways to reconstitute a 10 mg vial and the resulting unit math.

Worked example: Reconstitute a 10 mg vial with 2 mL of BAC water → 5 mg/mL. Each insulin unit holds 0.05 mg (50 mcg). A 0.5 mg test dose = 10 units; a 1.75 mg dose = 35 units. Diluting with more water (e.g., 5 mL) makes small test doses easier to measure accurately, which many clinicians prefer during titration.

Choosing a Reconstitution Volume

The choice of diluent volume is a trade-off. A smaller volume (1 mL) yields a concentrated solution where each dose is only a few units — economical on syringe volume but harder to measure precisely for small test doses, since a one- or two-unit error is proportionally large. A larger volume (5 mL) spreads the same 10 mg across more liquid, so a 0.5 mg test dose becomes 25 units — much easier to draw accurately, at the cost of injecting a slightly larger fluid volume. For patients titrating carefully through small test doses, many clinicians favor the more dilute preparation for exactly this reason. There is no single “correct” volume; the pharmacy and prescriber set it based on the intended dosing.

The Reconstitution Math, Generalized

The underlying formula is simple and worth internalizing: concentration (mg/mL) = total peptide (mg) ÷ diluent volume (mL). On a U-100 syringe, units to inject = desired dose (mg) ÷ concentration (mg/mL) × 100. So for a 10 mg vial in 2 mL (5 mg/mL) and a 1.0 mg target: 1.0 ÷ 5 × 100 = 20 units. This is the same arithmetic used for any reconstituted peptide, and double-checking it before each new vial is a core safety habit — a mis-set concentration is the most common source of accidental over- or under-dosing.

Bacteriostatic vs Sterile Water

Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits microbial growth and allows a multi-dose vial to be used over days to weeks. Plain sterile water lacks that preservative and is generally reserved for single-use preparation. For a multi-dose PT-141 vial, bacteriostatic water is the usual choice — but the specific diluent, volume, and beyond-use date should follow the compounding pharmacy’s and prescriber’s direction, not a generic internet protocol.

PT-141 Administration Guide

PT-141 is given as a subcutaneous injection — into the fat layer just under the skin, not into muscle.

Injection Site Selection

• Abdomen: at least an inch or two away from the navel, is the most common site.
• Thigh: the front/outer thigh is an alternative.
• Rotate sites each time. Repeated dosing in one spot raises the risk of focal skin darkening (hyperpigmentation), a known melanocortin effect.

Subcutaneous Injection Technique

1. Swab the site with alcohol and let it dry.
2. Pinch a fold of skin.
3. Insert a short 27–31 gauge insulin needle at 90° (a 45° angle for very lean patients).
4. Inject the measured dose slowly, then withdraw and apply light pressure.
5. Dispose of the needle in a sharps container.

Reducing Injection Discomfort and Bruising

A few practical points make subcutaneous dosing more comfortable: use a fresh, fine needle each time (needles dull quickly and a dull needle hurts more), let alcohol dry fully before inserting to avoid stinging, inject slowly, and avoid areas of visible veins to reduce bruising. If a site becomes reliably red or irritated, move to a different region rather than reusing it.

Handling and Storage

Keep reconstituted PT-141 refrigerated and protected from light. Do not freeze reconstituted solution — freezing can degrade the peptide. Discard any vial that is cloudy, discolored, or past its beyond-use date. Do not use a vial whose sterility is in doubt. Vyleesi autoinjectors are stored per the package label (room temperature within the limits stated, refrigerated for longer storage), and the pre-filled device removes any reconstitution or measuring step, which is one of its practical advantages over compounded vials.

Optimal Timing for PT-141 Administration

Timing is central to PT-141’s effect because it is used as needed, not on a daily schedule.

How Long Before Activity to Dose

The FDA label directs dosing at least 45 minutes before anticipated activity. Many clinicians describe a practical window of 30–60 minutes, and some patients dose up to a few hours ahead. Plasma concentrations peak roughly one hour after a subcutaneous injection.

How Long Does PT-141 Last?

Subjective effects commonly last about 4–8 hours. The elimination half-life is roughly 2.7 hours (published range about 1.9–4.0 hours), which is why a single as-needed dose covers an evening rather than the whole day.

How Long Does PT-141 Take to Work?

Onset is generally 30–60 minutes. Unlike a daily peptide, there is no “loading” period — each dose is taken for a specific occasion. Some people find the response builds a bit over the first few uses as they settle on the right dose and timing.

Food, Alcohol, and Timing

PT-141 does not require dosing on an empty stomach, but because nausea is the most common side effect, some patients prefer to dose with a light stomach rather than immediately after a heavy meal. Alcohol can amplify both nausea and flushing and can also independently blunt sexual response, so heavy drinking around a dose tends to work against the goal. The practical rhythm most patients settle into is a single planned dose, roughly 45 minutes to an hour ahead, without stacking it against a large meal or significant alcohol.

Why It Is Dosed As-Needed, Not Daily

Two factors drive the episodic dosing model: the short half-life (so there is no benefit to steady-state levels) and the side-effect profile (blood-pressure elevation and hyperpigmentation accumulate with frequency). Together they make PT-141 fundamentally an occasion-based therapy. Patients who find themselves wanting to dose daily are, in effect, signaling that either the underlying issue or their expectations need to be revisited with their physician.

PT-141 Cycle Length and Protocol Duration

PT-141 is fundamentally an as-needed therapy, so “cycling” looks different than it does for a daily growth-hormone-secretagogue peptide.

Frequency Caps

The Vyleesi label caps use at one dose per 24 hours and eight doses per month. Compounded protocols are commonly kept to no more than two to three uses per week. There is no evidence supporting daily dosing, and frequent dosing increases the cumulative blood-pressure and hyperpigmentation concerns.

When to Reassess

If someone finds they want to use PT-141 very frequently, that is a cue to reassess the underlying driver of low desire with their physician rather than simply increase frequency. The therapy is meant to complement a broader evaluation, not to be leaned on daily.

Do You Need “Time Off”?

Because PT-141 is used episodically rather than continuously, it does not require the wash-out or “off cycle” logic that applies to daily growth-hormone-secretagogue peptides. There is no established need to periodically stop for receptor recovery. The limiting factors are simply the per-dose and monthly frequency caps and the cumulative pigmentation concern, both of which are managed by keeping use occasional. If skin darkening appears, the appropriate response is to pause and reassess, not to push through.

PT-141 Safety Profile and Potential Side Effects

PT-141 has a well-characterized side-effect profile from the Vyleesi trials. The most important safety themes are gastrointestinal (nausea), cardiovascular (transient blood-pressure rise), and dermatologic (flushing and hyperpigmentation).

Common Side Effects

The nausea deserves particular attention because it is the side effect most likely to make patients abandon the therapy. It clusters around the first injection, tends to lessen with subsequent doses, and can be managed with expectation-setting and, when appropriate, an anti-nausea medication. It is rarely dangerous, but it is common enough that any honest counseling includes it up front. Flushing and headache are typically mild and self-limited.

Cardiovascular Caution: Transient Blood-Pressure Rise

Bremelanotide causes a transient increase in blood pressure and a small decrease in heart rate after each dose. In ambulatory monitoring the average daytime systolic rise was on the order of ~2 mmHg, with peak increases around 2.8 mmHg systolic occurring roughly 4–8 hours after dosing and peak diastolic increases around 2.7 mmHg in the first hours — modest on average, but real, and the reason the higher-exposure intranasal route was abandoned during development. The effect is transient, resolving as the drug clears, but it is a genuine pharmacologic action, not a rare idiosyncratic reaction.

Because of this, PT-141 is not appropriate for people with uncontrolled hypertension or known cardiovascular disease, and blood pressure should be controlled and documented before use. This single caution is the most important reason PT-141 is a physician-supervised therapy rather than a casual over-the-counter-style product: the patients most likely to seek it (middle-aged adults with sexual complaints) overlap heavily with the patients most likely to have undiagnosed or borderline hypertension. A blood-pressure check is not a formality here — it is the gatekeeping safety step.

Contraindications

• Uncontrolled high blood pressure or known cardiovascular disease.
• Pregnancy (Vyleesi is not for use in pregnancy; effective contraception is advised in relevant patients).
• Predisposition to hyperpigmentation disorders (relative caution).
• Postmenopausal women and men fall outside the approved indication and require an explicit off-label discussion.

Drug Interactions

Bremelanotide can slow gastric emptying, which may reduce the absorption of certain oral medications — a notable interaction is with naltrexone and other orally administered drugs where reduced absorption matters, potentially lowering their effect. Combining with other agents that raise blood pressure warrants caution. Alcohol may compound nausea and flushing. Always give your physician a full medication and supplement list.

Hyperpigmentation: A Melanocortin-Specific Concern

Because bremelanotide activates MC1R on skin melanocytes, repeated dosing can cause focal hyperpigmentation — darkening of the skin, and sometimes the face and gums. It is more likely with more frequent use and in people with darker baseline skin tone, and it may not fully reverse after stopping. This is a class effect shared with other melanocortin peptides such as Melanotan. Rotating injection sites, keeping use infrequent, and stopping at the first sign of unexpected darkening are the practical mitigations. New or changing pigmented lesions should always be evaluated, since distinguishing benign drug-related pigment change from something that needs dermatologic attention is a clinician’s job.

Special Populations

PT-141 has not been established as safe in pregnancy and should not be used by pregnant patients; women who could become pregnant should use effective contraception per their physician’s guidance. Caution and dose consideration apply in significant hepatic or renal impairment. It has not been studied in adolescents. Older adults and anyone with cardiovascular risk factors need the blood-pressure evaluation described above before any use.

Combining PT-141 With Other Peptides and Therapies

PT-141 targets desire and central arousal. Patients and clinicians sometimes look at how it sits alongside other therapies. The matrix below compares it against adjacent options by mechanism — as physician-directed education, not a stacking recommendation.

Stacking PT-141 with a PDE5 inhibitor or with hormone therapy is a physician decision that hinges on blood pressure, cardiac status, and the actual cause of the complaint. It should never be self-assembled from separate online purchases.

What About PT-141 and Melanotan?

PT-141 is a metabolite of Melanotan II, another melanocortin peptide marketed for tanning. They share the hyperpigmentation and nausea effects. BHRC does not endorse unregulated tanning-peptide use; the melanocortin family’s skin-darkening and cardiovascular effects are precisely why physician oversight matters.

Who Should Consider PT-141 Therapy?

PT-141 is worth a physician conversation for a specific profile of patients, and clearly not for others.

Potentially Appropriate Candidates

• Premenopausal women with acquired, generalized HSDD (the approved Vyleesi indication).
• Men with low libido or desire-related sexual dysfunction, including some who do not respond to PDE5 inhibitors (off-label).
• Patients who want a non-daily, as-needed option and who have controlled blood pressure.

Who Should Not Use PT-141

• Anyone with uncontrolled hypertension or established cardiovascular disease.
• Pregnant patients.
• People whose low desire is better explained by a treatable cause — low testosterone, depression, medication side effects, relationship or situational factors — which should be addressed first.

Schedule a Peptide Therapy Consultation so a BHRC physician can evaluate your history, blood pressure, and goals before any therapy is considered.

Monitoring Progress and Adjusting Protocols

Because PT-141 affects blood pressure and skin pigmentation, monitoring is part of responsible use.

What to Track

• Blood pressure: established as controlled before starting, and rechecked; note that each dose transiently raises it.
• Tolerability: nausea severity, especially after the first dose, and whether pretreatment is needed.
• Skin: watch for new or spreading hyperpigmentation, which is a signal to reduce frequency or stop.
• Response: whether the dose and timing are actually producing the desired effect, so the plan can be refined.

When to Adjust

Titration is usually about tolerability, not chasing a bigger effect — most adjustment happens between the 0.5 mg test dose and the 1.0–1.75 mg working dose. If side effects dominate, the answer is a lower dose, less frequent use, or stopping — not a higher dose.

Defining Success Honestly

Because the studied effect size is modest, it helps to set realistic expectations before starting. Success with PT-141 typically looks like a meaningful improvement in desire or arousal on some occasions, not a dramatic transformation on every use. A reasonable check-in framework is: after several as-needed uses, does the patient report a worthwhile benefit that outweighs the nausea and other effects? If yes, continue at the lowest effective dose. If the benefit is marginal and the side effects are bothersome, PT-141 may simply not be the right therapy for that person, and continuing to escalate is the wrong move.

When to Stop

Clear stop signals include a sustained rise in blood pressure, new or spreading hyperpigmentation, severe or persistent nausea and vomiting, any concerning cardiovascular symptom, or simply a consistent lack of benefit. Stopping PT-141 requires no taper — because it is used episodically, discontinuation is simply not taking the next dose.

Is PT-141 FDA-Approved? Legal & Regulatory Status (2026)

This is where PT-141 and Vyleesi part ways, and it must be stated precisely.

What Is Approved

Vyleesi (bremelanotide 1.75 mg subcutaneous injection) is FDA-approved (2019) for the treatment of premenopausal women with acquired, generalized HSDD. That is the entire scope of the approval. It is not approved for men, not for postmenopausal women, and not for HSDD due to another medical/psychological cause, relationship issues, or a medication.

What Is Not Approved

Every other use — PT-141 in men, compounded injectable “peptide therapy,” and any nasal-spray form — is off-label and/or compounded and is not FDA-approved. There is no FDA-approved bremelanotide nasal spray of any kind.

Compounding Rules: 503A, Category 2, and “Copies”

Because an FDA-approved bremelanotide product exists, compounding is constrained. Bremelanotide sits in the FDA’s Category 2 grouping used in the agency’s peptide review, and the “essentially a copy of a commercially available drug product” restriction under section 503A applies. In practice that means a 503A pharmacy generally may compound PT-141 only when a prescriber documents a patient-specific clinical need for a change from the approved Vyleesi product (for example, a different dose or route). These restrictions are current as of July 24, 2026, and the regulatory landscape for peptides is actively evolving — status should be re-verified before relying on it.

The route-of-administration nuance is worth understanding because it is sometimes used to justify products: FDA guidance treats a compounded preparation that differs from the approved product in a clinically meaningful way — such as a genuinely different route — as potentially not an “essentially a copy.” This is the rationale sometimes offered for sublingual troches or other non-injectable forms. That is a regulatory argument to be made by a licensed prescriber and pharmacy for a specific patient, not a blanket green light, and it does not make such products FDA-approved.

Why BHRC Treats This as Physician-Supervised Only

The combination of a real cardiovascular action, a class-specific pigmentation effect, and a compounding landscape where product quality varies is exactly why Beverly Hills Rejuvenation Center positions PT-141 as a physician-evaluated, physician-supervised therapy. We do not sell raw or “research-only” peptide, and we do not treat PT-141 as a lifestyle purchase. The appropriate path is an evaluation that screens blood pressure and underlying causes, confirms candidacy, and — where the indication fits — considers the FDA-approved product first.

Athletic / Anti-Doping Note

Athletes subject to WADA/USADA testing should confirm current prohibited-substance status with their governing body before using any melanocortin peptide, as classification and interpretation can change over time.

Conclusion

PT-141 (bremelanotide) is a melanocortin MC4R agonist that acts on the brain’s desire and arousal pathways — a fundamentally different mechanism from Viagra-style blood-flow drugs. The FDA-approved product, Vyleesi, is dosed at a fixed 1.75 mg subcutaneously, at least 45 minutes before activity, capped at one dose per 24 hours and eight per month, and is approved only for premenopausal women with acquired, generalized HSDD. Physician-directed compounded PT-141 protocols typically start at a 0.5 mg test dose, settle at 1.0–1.75 mg, cap near 2 mg, and are used a few times per week at most. The real safety levers are the transient blood-pressure rise (making cardiovascular screening essential), first-dose nausea, and hyperpigmentation with repeated use. Whether the right answer is the FDA-approved product, a compounded protocol, or a different therapy entirely is a decision to make with a physician — not from an online vendor.

Schedule a Peptide Therapy Consultation with Beverly Hills Rejuvenation Center to review your candidacy under physician supervision.

Frequently Asked Questions About PT-141 Dosing

What is the standard PT-141 dosage?

The FDA-approved dose (Vyleesi) is 1.75 mg subcutaneously, at least 45 minutes before anticipated activity, no more than once in 24 hours and no more than 8 times per month. Compounded protocols often start at a 0.5 mg test dose and build to 1.0–1.75 mg.

What is a good starting or test dose of PT-141?

Clinicians commonly begin with a 0.5 mg test dose (some use 0.25–1.0 mg) to gauge nausea and blood-pressure response before any regular use, then titrate upward only if it is well tolerated.

How much PT-141 is the maximum dose?

Around 2 mg per dose is the practical ceiling. Doses above roughly 1.75–2 mg increase nausea and blood-pressure effects without adding clear benefit. The approved product is a fixed 1.75 mg.

How long before activity should I take PT-141?

At least 45 minutes before, per the label; many clinicians describe a 30–60 minute window. Blood levels peak about an hour after a subcutaneous injection.

How long does PT-141 last and how long does it take to work?

Onset is typically 30–60 minutes, and effects generally last about 4–8 hours. The half-life is roughly 2.7 hours, which is why it is dosed as-needed rather than daily.

How often can I use PT-141?

No more than one dose in 24 hours. The Vyleesi label caps use at 8 doses per month; compounded protocols are commonly kept to no more than 2–3 times per week. It is not a daily medication.

How do I convert a PT-141 dose to insulin units?

It depends on how the vial is reconstituted. A 10 mg vial in 2 mL of bacteriostatic water is 5 mg/mL, so on a U-100 syringe each unit holds 0.05 mg: a 0.5 mg dose is 10 units and 1.75 mg is 35 units. Reconstituting a 10 mg vial in 1 mL makes 1.75 mg equal 17.5 units.

Is there a PT-141 nasal spray, and what is its dose?

There is no FDA-approved bremelanotide nasal spray. The original nasal program was abandoned around 2008 after it caused dose-dependent blood-pressure increases, and development moved to the lower-dose subcutaneous injection. Any nasal product is unapproved and unstandardized.

What is the difference between PT-141 and Vyleesi?

They are the same molecule (bremelanotide). Vyleesi is the FDA-approved, fixed-dose 1.75 mg autoinjector for premenopausal women with HSDD. “PT-141” refers to compounded or research forms used off-label, including in men, which are not FDA-approved.

Is PT-141 safe with high blood pressure?

Not without careful evaluation. Bremelanotide causes a transient rise in blood pressure with each dose, so it is not appropriate for people with uncontrolled hypertension or known cardiovascular disease. Blood pressure must be controlled and monitored under physician supervision.

Related Resources / Related Blogs from BHRC

Explore other physician-supervised peptide dosage guides from Beverly Hills Rejuvenation Center:

• CJC-1295 / Ipamorelin — growth-hormone-secretagogue peptide therapy.
• Tirzepatide — GLP-1/GIP metabolic and weight-management therapy.
• MOTS-c — mitochondrial-derived peptide for metabolism and energy.
• AOD-9604 — fat-metabolism peptide dosage guide.
• BPC-157 dosage guide — tissue-repair peptide (sibling guide in this series; confirm final slug).
• Retatrutide dosage guide — triple-agonist metabolic peptide (sibling guide in this series; confirm final slug).

Schedule a Peptide Therapy Consultation to discuss which physician-supervised peptide therapy fits your goals.

References

1. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. PMID: 31599840. https://pubmed.ncbi.nlm.nih.gov/31599840/
2. Simon JA, Kingsberg SA, Portman D, et al. The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results. PMID: 33538638. https://pubmed.ncbi.nlm.nih.gov/33538638/
3. VYLEESI (bremelanotide injection) Highlights of Prescribing Information. U.S. Food & Drug Administration, 2019 (NDA 210557). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
4. VYLEESI (bremelanotide injection) Label. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf
5. Bremelanotide. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf, NBK573221. https://www.ncbi.nlm.nih.gov/books/NBK573221/
6. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With HSDD (RECONNECT). ClinicalTrials.gov, NCT02333071. https://clinicaltrials.gov/study/NCT02333071
7. Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the FD&C Act — Guidance for Industry. U.S. Food & Drug Administration. https://www.fda.gov/media/98964/download

About the author: Sam Brooks is a member of the Beverly Hills Rejuvenation Center peptide education team, focused on translating clinical literature into plain-English patient education.

Medically reviewed by: the BHRC Clinical Team — Beverly Hills Rejuvenation Center. The BHRC clinical team reviewed this guide for clinical accuracy on July 24, 2026. This content is educational and does not replace an individual medical evaluation.